RISalud-ANDALUCÍA
Not a member yet
18682 research outputs found
Sort by
Interaction of an S100A9 gene variant with saturated fat and carbohydrates to modulate insulin resistance in 3 populations of different ancestries.
No full textS100 calcium-binding protein A9 (S100A9) has previously been identified as a type 2 diabetes (T2D) gene. However, this finding requires independent validation and more in-depth analyses in other populations and ancestries. We aimed to replicate the associations between an S100A9 variant and insulin resistance and T2D and to initiate an investigation of potential interactions with the habitual diet in several independent populations. We investigated the association of the S100A9 variant rs3014866 with insulin resistance and T2D risk and its interactions with diet in 3 diverse populations as follows: the CORDIOPREV (Coronary Diet Intervention with Olive Oil and Cardiovascular Prevention; n = 711), which consisted of Spanish white adults; the GOLDN (Genetics of Lipids Lowering Drugs and Diet Network; n = 818), which involved North American non-Hispanic white adults; and Hispanic adults who participated in the BPRHS (Boston Puerto Rican Health Study; n = 1155). Meta-analysis indicated that T carriers presented a lower risk of T2D than CC carriers (pooled OR: 0.714; 95% CI: 0.584, 0.845; P = 0.002). In all 3 populations (CORDIOPREV, GOLDN, and BPRHS), we showed a significant interaction between the rs3014866 single nucleotide polymorphism and dietary SFA:carbohydrate ratio intake for the homeostasis model assessment of insulin resistance (HOMA-IR) (P = 0.028, P = 0.017, and P = 0.026, respectively). CC carriers had a significantly higher HOMA-IR only when SFA:carbohydrate intake was high (P = 0.045 for the CORDIOPREV, P = 0.033 for the GOLDN, and P = 0.046 for the BPRHS) but not when SFA:carbohydrate ratio intake was low. The minor allele (T) of the S100A9 variant rs3014866 is associated with lower T2D risk in 3 populations of different ancestries. Note that individuals with the high-risk CC genotype may be more likely to benefit from a low SFA:carbohydrate ratio intake to improve insulin resistance as evaluated with the use of the HOMA-IR.S
Vol. 28, nº 32. Evaluación del plan de inspección basado en el riesgo de actividades de tatuajes, micropigmentación y piercing, PIBR-TMP: resultados de la programación 2022 y plan de acción
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 31/2023 y acumulado desde la semana 01/2023. Datos provisionales. Incluye además el artículo titulado “Evalaución del plan de inspección basado en el riesgo de actividades de tatuajes, micropigmentación y piercing, PIBR-TMP: resultados de la programación 2022 y plan de acción”, de “Juan Antonio Ortiz Batanero, José Enrique Fernández Alcauza, Francisco José Marchena Fernández”.Ye
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
No full textProgrammed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G1 subtype with a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, we present results of the pivotal study of patients with metastatic CSCC from an open-label, multicenter, multiregional, multicohort, phase 1 trial of cosibelimab.MethodsIn this trial, participants with metastatic CSCC received cosibelimab 800 mg intravenously every 2 weeks. Primary endpoint was objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, V.1.1. Secondary endpoints included duration of response (DOR) and safety.ResultsObjective response was observed in 37 of 78 participants (47.4% (95% CI: 36.0% to 59.1%)), with median follow-up of 15.4 months (range: 0.4 to 40.5) as of data cut-off. Median DOR was not reached (range: 1.4+ to 34.1+ months), with response ongoing in 73.0% of participants. Common treatment-emergent AEs (>= 15%) were fatigue (26.9%), rash (16.7%), and anemia (15.4%). Eighteen participants (23.1%) experienced immune-related AEs (grade 3: n=2 (2.6%); no grade 4/5). No treatment-related deaths were reported.ConclusionsCosibelimab demonstrated clinically meaningful ORR and DOR and was associated with a manageable safety profile.Ye
Proceso asistencial a la persona con riesgo de conducta suicida en emergencias prehospitalarias
No full textUn manejo adecuado de los pacientes con conducta suicida puede contribuir a reducir las tasas de morbilidad y mortalidad de la conducta suicida, y uno de los elementos esenciales para conseguir este manejo adecuado es la formación. La creación de protocolos para guiar y establecer consenso entre los distintos profesionales con capacidad de tomar decisiones en estas situaciones, dentro y fuera de los hospitales, mejoraría la implicación y la inclusión de estas personas en redes de salud, permitiendo su monitorización por profesionales de atención comunitaria con un punto de vista de la prevención del suicidio.Ye
Drug-loaded PCL electrospun nanofibers as anti-pancreatic cancer drug delivery systems
No full textCancer is one of the main causes of death worldwide, being pancreatic cancer the second deadliest cancer in Western countries. Surgery, chemotherapy and radiotherapy form the basis of pancreatic cancer's current treatment. However, these techniques have several disadvantages, such as surgery complications, chemotherapy systemic side effects and cancer recurrence. Drug delivery systems can reduce side effects, increasing the effectivity of the treatment by a controlled release at the targeted tumor cells. In this context, coaxial electrospun fibers can increase the control on the release profile of the drug. The aim of this study was to encapsulate and release different anticancer drugs (5-Fluorouracil and Methotrexate) from a polymeric fiber mat. Different flows and ratios were used to test their effect on fiber morphology, FTIR spectrum, drug encapsulation and release. Good integration of the anticancer drugs was observed and the use of a desiccator for 24 h showed to be a key step to remove solvent remanence. Moreover, the results of this study demonstrated that the polymeric solution could be used to encapsulate and release different drugs to treat cancers. This makes coaxial electrospinning a promising alternative to deliver complex chemotherapies that involve more than one drug, such as FOLFIRINOX, used in pancreatic cancer treatment.S
Vol. 28, nº 46. Lesiones producidas por animales: protocolo de actuación del distrito sanitario Málaga -Valle del Guadalhorce
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 45/2023 y acumulado desde la semana 01/2023. Datos provisionales. Incluye además el artículo titulado “Lesiones producidas por animales: protocolo de actuación del distrito sanitario Málaga -Valle del Guadalhorce”, de “María José Ortega Belmonte, Sofía Lorenzo Pérez, César Rodríguez García”.Ye
Vol. 28, nº 31. La evalaución de riesgos en salud
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 30/2023 y acumulado desde la semana 01/2023. Datos provisionales. Incluye además el artículo titulado “La evalaución de riesgos en salud”, de “Manuel Jesús Viñas Casasola”.Ye
Mortalidad durante los dos primeros años de la pandemia de COVID-19 en Andalucía: cambios y variabilidad entre distritos sanitarios
No full textEste estudio pretende acercarse al impacto de la pandemia de COVID-19 en la mortalidad en Andalucía, analizando la evolución de la mortalidad en Andalucía entre el periodo prepandemia (trienio 2017-2019) y los dos primeros años de la pandemia de COVID-19 (2020-2021), tanto en la mortalidad total como por las principales causas y la mortalidad prematura.Ye
Información sobre las posibilidades de tratamiento con medicamentos de terapias avanzadas fabricados en el SSPA: En cartera de servicios dentro de ensayos clínicos en marcha en el marco de la Red Andaluza de diseño y traslación de Terapias Avanzadas bajo uso compasivo
No full textDocumento a remitir a las direcciones gerencias de los hospitales del Servicio Andaluz de Salud para su difusión a los Servicios Asistenciales Médicos y Quirúrgicos correspondientes, con el objetivo de facilitar el acceso EQUITATIVO de los pacientes a los tratamientos de terapias avanzadas dentro del Servicio Andaluz de Salud.N
Vol. 28, nº 06. Viruela del mono: del diagnóstico al seguimiento desde la atención primaria.
No full textEnfermedades de Declaración Obligatoria por provincias. Semana 05/2022 y acumulado desde semana 01/2022. Datos provisionales. Incluye además el artículo titulado "Viruela del mono: del diagnóstico al seguimiento desde la atención primaria", de "Francisco Javier Pacheco Calvente", Médico de familia. Consultorio Aguadulce Norte. UGC Aguadulce-El Parador. Distrito Poniente de Almería.Ye